Informing patients of the risks and benefits of hormone replacement therapy: Nephrologists’ ethical obligation

References 

1. Women’s Health Initiative Study Group . Risks and benefits of estrogen plus progestin in healthy postmenopausal women (Principal results from the Women’s Health Initiative randomized controlled trial) . JAMA . 2002;288:321–333
   • MEDLINE
   • CrossRef
2. Hulley S , Furberg C , Barrett-Connor E , et al.   Noncardiovascular disease outcomes during 6.8 years of hormone therapy (Heart and Estrogen/progestin Replacement Study follow-up (HERS II)) . JAMA . 2002;288:58–66
   • MEDLINE
   • CrossRef
3. U.S. Preventive Services Task Force . Postmenopausal hormone replacement therapy for primary prevention of chronic conditions (Recommendations and rationale) . Ann Intern Med . 2002;137:834–839
4. Alving B . NIH asks participants in Women’s Health Initiative estrogen alone study to stop study pills and begin follow up phase . NIH News . U.S. Dept of Health and Human Services: NHLBI; 2004; March 2
5. Lo B . Resolving Ethical Dilemmas (A Guide for Clinicians) . (ed 2). Philadelphia, PA: Lippincott Williams & Wilkins; 2002;
6. Beauchamp TL , Childress JF . Principles of Biomedical Ethics . (ed 4). New York, NY: Oxford University Press; 2000;
7. Beauchamp TL . The four principles’ approach . In:  Raanan Gillon editors. Principles of Health Care Ethics . New York, NY: John Wiley and Sons; 1994;p. 4
8. Henderson JL . Physician and patient as a social system . N Engl J Med . 1935;212:823
   • CrossRef
9. Pelligrino E . In: For the Patients Good . New York, NY: Oxford; 1988;p. 10